

**AMENDMENTS TO THE SPECIFICATION**

On page 1, following the title, please amend the first paragraph as follows:

**CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a 35 U.S.C. § 371 filing of PCT/US2005/003245, filed February 3, 2005. PCT/US2005/003245 ~~This application~~ claims the benefit of the following U.S. Applications: 60/542,780, filed February 5, 2004; 60/556,831 filed March 26, 2004; 60/575,919 filed June 1, 2004; and 10/912,932 filed August 6, 2004. The disclosures of all of the aforementioned applications are incorporated by reference in their entireties for all purposes.

On page 1, following the Cross-Reference to Related Application section, please add the following:

**STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED  
RESEARCH**

Not applicable.

Please insert the following Abstract on new page 128:

**ABSTRACT OF THE DISCLOSURE**

Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region.

The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, as well as polynucleotides encoding same. Fusion proteins comprising cleavage half-domains are used in pairs, to reconstitute a functional cleavage domain. In these fusion proteins, the zinc finger domain can be N-terminal to the cleavage half-domain, or the cleavage half-domain can be N-terminal to the zinc finger domain. The availability of fusion endonucleases having these different polarities allows targeting (and thereby binding) of zinc finger endonucleases either to opposite strands of the DNA target or

to the same strand of the DNA target, thereby increasing the number of possible sequences which can be targeted and cleaved by the fusion proteins.

Attachment: Page 128 consisting of the Abstract